ATLANTA, Nov. 24 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it is scheduled to participate in the 20th Annual Piper Jaffray Health Care Conference at The New York Palace Hotel on December 2, 2008.
Steven G. Anderson, president and chief executive officer of CryoLife, Inc., will provide a corporate overview and host a question and answer session at 2:30 p.m. Eastern Time.
CryoLife's live presentation may be accessed through its Web site, www.cryolife.com , on the Investor Relations page. An archived copy of the presentation will be available for 90 days on the same Web site.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company has received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH(R), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom, Germany, France, and Canada for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine Aortic Bioprosthesis, which is CE marked for distribution within the European Community.
For additional information
|SOURCE CryoLife, Inc.|
Copyright©2008 PR Newswire.
All rights reserved